With over $4 billion in halted NIH grants and defunded university programs, clinical trials and scientific innovation are facing unprecedented disruption. As legal challenges mount, life sciences leaders and legal professionals must navigate the fallout. Topics of discussion include:

• The impacts of halted funding on clinical trials and drug development
• Analyzing ongoing lawsuits against the NIH and updates on the broader legal fight to restore funding
• The consequences of defunding universities and health equity programs on future medical breakthroughs
• How life sciences companies and legal advisors can respond to the disruption, from compliance strategies to managing potential private litigation risks